← All indications
Lymphohistiocytosis, Hemophagocytic
A group of related disorders characterized by LYMPHOCYTOSIS; HISTIOCYTOSIS; and hemophagocytosis. The two major forms are familial and reactive.
Drugs by status
Approved for this indication (1)
Phase 4 trials (6)
Phase 3 trials (14)
Phase 2 trials (18)
Phase 1 trials (10)
Organizations
Organization Involved with Phase 3 Indications (16)
- NovImmune SA
- Baylor University
- Children's Cancer and Leukaemia Group
- University of London
- Hospital JP Garrahan
- St. Anna Kinderkrebsforschung
- University of Florence
- University of Hamburg
- Capital Medical University
- University of Cincinnati
- Leiden University
- University of Minnesota
- Karolinska Institute
- Osakidetza
- Watford General Hospital
- Ehime University
Organization Involved with Phase 2 Indications (18)
- Incyte
- Atara Biotherapeutics
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- University of Pennsylvania
- Medical College of Wisconsin
- Nanjing Medical University
- North American Consortium for Histiocytosis
- University of Florida
- University of Texas at Houston
- Methodist Cancer Center, Houston, Texas
- University of Paris
- Washington University in St. Louis
- Capital Institute of Pediatrics, China
- Blood and Marrow Transplant Clinical Trials Network
- Capital Research Institute of Pediatrics
- St. Jude Children's Hospital
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (3)